Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTME
2024-516125-31-02Phase 2Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab, peginterferon alfa-2a and GC101 TIL + pembrolizumab in melanoma (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Safety and toxicity of TIL and nivolumab, and of PEG-IFNα, nivolumab and TIL. Planned start Dec 2024; status: authorised.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2024-516125-31-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516125-31-02.